Skip to main content
SpringerLink
Log in

Uses of polymerase chain reaction in leukemia: Detection of minimal residual disease and identification of novel genetic mutations

  • Chapter
Leukemia: Advances in Research and Treatment

Part of the book series: Cancer Treatment and Research ((CTAR,volume 64))

  • 58 Accesses

Abstract

Polymerase chain reaction (PCR) is a new molecular technique that allows in vitro amplification up to millions of copies of the target DNA [1]. It was initially used to facilitate the specific identification of hereditary genetic disorders with a point mutation. Its clinical usefulness is overtly evident, because it requires only very small amounts of samples and also because the whole assay can be completed within a very short period of time (ranging from a few hours to a couple of days).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Saiki RK, Gelfand DH, Stoffel S, Sharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich MA, Arnheim N (1985). Enzymatic amplification of alpha-globulin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230: 1350–1354.

    Article  PubMed  CAS  Google Scholar 

  2. Lee MS, Chang KS, Cabanillas F, Freireich EJ, Trujillo JM, Stass SA (1987). Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science 237: 175–178.

    Article  PubMed  CAS  Google Scholar 

  3. Lee MS, Chang KS, Freireich EJ, Kantarjian HM, Talpaz M, Trujillo JM, Stass SA (1988). Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction. Blood 72: 893–897.

    PubMed  CAS  Google Scholar 

  4. Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON, McCormick FP (1988). Diagnosis of chronic myelogenous leukemia and acute leukemia by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci USA 85: 5689–5692.

    Article  Google Scholar 

  5. Lee MS, Lemaistre A, Kantarjian HM, Talpaz M, Freireich EJ, Trujillo JM, Stass SA (1989). Detection of two alternative bcr/abl mRNA and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction. Blood 73: 2165–2170.

    PubMed  CAS  Google Scholar 

  6. Yamada M, Hudson S, Tournay O, Bittenbender S, Shane SS, Lange B, Trujimoto Y, Canton AJ, Rovera G (1989). Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes. Proc Natl Acad Sci USA 86: 5122–5127.

    Google Scholar 

  7. Tycko B, Palmer JD, Link MP, Smith SD, Sklar J (1989). Polymerase chain reaction amplification of rearranged antigen receptor genes using junction-specific oligonucleotides: possible application for detection of minimal residual disease in acute lymphoblastic leukemia. Cancer Cells 7: 47–52.

    CAS  Google Scholar 

  8. Canellos GP (1976). Chronic granulocytic leukemia. Med Clin North Am 60: 1001–1018.

    PubMed  CAS  Google Scholar 

  9. Goldman JM, Lu DP (1982). New approaches in chronic granulocytic leukemia—origin, prognosis and treatment. Semin Hematol 19: 241–256.

    PubMed  CAS  Google Scholar 

  10. Sokal JE (1979). Evaluation of survival data from chronic myelogenous leukemia. Am J Hematol 1: 493–500.

    Article  Google Scholar 

  11. Kantarjian HM, Smith TL, McCredie KB (1985). Chronic myelogenous leukemia: A multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 66: 1326–1335.

    PubMed  CAS  Google Scholar 

  12. Thomas ED, Clift RA, Fefer A, Applebaum FR, Beatty P, Bensinger WI, Buckner CD, Cheever MA, Deeg HJ, Doney K, Flournoy N, Greenberg P, Hansen JA, Martin P, McGuffin R, Ramberg R, Sanders JE, Singer J, Stewart P, Storb R, Sullivan K, Weiden PL, Witherspoon R (1986). Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104: 155–163.

    PubMed  CAS  Google Scholar 

  13. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo JM, Gutterman J (1987). Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69: 1280–1288.

    PubMed  CAS  Google Scholar 

  14. Rowley JD (1973). A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290–293.

    Article  PubMed  CAS  Google Scholar 

  15. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G (1984). Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36: 93–99.

    Article  PubMed  CAS  Google Scholar 

  16. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G (1985). Structural organization of the bcr gene and its role in the Ph’ translocation. Nature 315: 758–761.

    Article  PubMed  CAS  Google Scholar 

  17. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, Grosveld G (1983). Localization of the c-abl oncogene adjacent to a translocation breakpoint in chronic myelogenous leukemia. Nature 306: 239–242.

    Article  PubMed  CAS  Google Scholar 

  18. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E (1986). Alternative splicing of RNAs transcribed from the human abl gene and from the bcr/abl fused gene. Cell 47: 277–284.

    Article  PubMed  CAS  Google Scholar 

  19. Talpaz M, Kantarjian HM, Kurzrock R, Gutterman J (1990). Update on therapeutic options for chronic myelogenous leukemia. Semin Hematol 27(Suppl 4): 31–36.

    PubMed  CAS  Google Scholar 

  20. Lee MS, Kantarjian HM, Freireich EJ, Deisseroth A, Trujillo JM, Stass SA (in press). Detection of minimal residual disease by Polymerase Chain Reaction in Philadelphia Chromosome positive chronic myelogous leukemia. Blood.

    Google Scholar 

  21. Gabert, J, Lafage M, Maranichi D, Thuret I, Carcassonne Y, Mannoni P (1989). Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukemia patients after bone-marrow transplantation. Lancet 11: 1125–1127.

    Article  Google Scholar 

  22. Sawyers CL, Timson L, Kawasaki ES, Clark SS, Witte ON, Champlin R (1990). Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proc Natl Acad Sci USA 87: 563–567.

    Article  PubMed  CAS  Google Scholar 

  23. Roth MS, Antin JH, Bingham EL, Ginsburg D (1989). Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia. Blood 74: 882–885.

    PubMed  CAS  Google Scholar 

  24. Hughes T, Martiat P, Morgan G, Sawyers C, Witte O, Goldman JM (1990). Significance of residual leukemia transcripts after bone marrow transplant for CML. Lancet 1: 50.

    Article  Google Scholar 

  25. Hughes TP, Morgan GJ, Martiat P, Goldman JM (1991). Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 77: 874–878.

    PubMed  CAS  Google Scholar 

  26. Pignon JM, Henni T, Amselem S, Vidaud M, Duquesnoy P, Vernant JP, Kuentz M, Cordonnier C, Rochant H, Goossens M (1990). Frequent detection of minimal residual disease by use of the polymerase chain reaction in long term survivors after bone marrow transplantation for chronic myeloid leukemia. Leukemia 4: 83–86.

    PubMed  CAS  Google Scholar 

  27. Snyder DS, Rossi JJ, Wang JL, Sniecinski IJ, Slovak ML, Wallace RB, Forman SJ (1991). Persistence of bcr-abl gene expression following bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Transplantation 51: 1033–1040.

    Article  PubMed  CAS  Google Scholar 

  28. Kwok S, Higuchi R, (1989). Avoid false positives with PCR. Nature 339: 237–238.

    Article  PubMed  CAS  Google Scholar 

  29. Yamada M, Wasserman R, Lange B, Reichard B, Womer RB, Rovera G (1990). Minimal residual disease in childhood B-lineage lymphobalstic leukemia: persistence of leukemic cell during the first 18 months of treatment. N Engl J Med 323: 448–455.

    Article  PubMed  CAS  Google Scholar 

  30. Lee MS, Estov Z, Zipf T (manuscript in preparation).

    Google Scholar 

  31. Chen GL, Yang L, Rowe TC (1984). Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. Biol Chem 259: 13560–13566.

    CAS  Google Scholar 

  32. Liu LF (1989). DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351–375.

    Article  PubMed  CAS  Google Scholar 

  33. Ross W (1985). DNA topoisomerases as targets for cancer therapy. Biochem Pharmacol 34: 4191–4195.

    Article  PubMed  CAS  Google Scholar 

  34. Beran M, Anderson BS (1987). Development and charaterization of a human myelogenous leukemia cell line resistant to 4’-(9-acridinylamino)-3-methane-sulfon-m-anisidide. Cancer Res 47: 1897–1904.

    PubMed  CAS  Google Scholar 

  35. Lee MS, Vang J, Beran M (1992). Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kD form of human topoisomerase II. J Mol Biol 223: 837–843.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Ming-Sheng Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sanford A. Stass
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. M.D. Anderson Cancer Center, The University of Texas, USA

    Emil J. Freireich  & Hagop Kantarjian  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media New York

About this chapter

Cite this chapter

Lee, MS., Stass, S.A. (1993). Uses of polymerase chain reaction in leukemia: Detection of minimal residual disease and identification of novel genetic mutations. In: Freireich, E.J., Kantarjian, H. (eds) Leukemia: Advances in Research and Treatment. Cancer Treatment and Research, vol 64. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3086-2_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3086-2_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6348-4

  • Online ISBN: 978-1-4615-3086-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation